Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Reata Pharmaceuticals (RETA) stocks

Learn how to easily invest in Reata Pharmaceuticals stocks.

Reata Pharmaceuticals is a biotechnology business based in the US. Reata Pharmaceuticals stocks (RETA.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $139.36 – an increase of 0.95% over the previous week. Reata Pharmaceuticals employs 346 staff and has a trailing 12-month revenue of around $10 million.

How to buy stocks in Reata Pharmaceuticals

  1. Compare stock trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – RETA – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of stocks with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Reata Pharmaceuticals stock price (NASDAQ:RETA)

Use our graph to track the performance of RETA stocks over time.

Reata Pharmaceuticals shares at a glance

Information last updated 2022-10-03.
Latest market close$25.52
52-week range$18.47 - $114.80
50-day moving average $25.76
200-day moving average $28.98
Wall St. target price$50.67
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-8.35

Compare stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

1 - 5 of 5
Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
CIBC Investor's Edge
Finder Rating:
4 / 5
$0 if conditions met, else $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Young investors 18 to 24 can get free online trades and a $0 annual account fee. Conditions apply.
Interactive Brokers
Finder Rating:
4.1 / 5
min $1.00, max 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Finder Rating:
3.9 / 5
Stocks, ETFs
Get $25 when you open a Wealthsimple account and fund at least $150.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get almost $500 in commission free trades when you fund your new account with a minimum of $10,000. Conditions apply. Ends October 31, 2022.

Compare up to 4 providers

Is it a good time to buy Reata Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Reata Pharmaceuticals price performance over time

Historical closes compared with the close of $25.52 from 2022-10-04

1 week (2022-09-28) 0.95%
1 month (2022-09-01) 0.12%
3 months (2022-07-05) -30.06%
6 months (2022-04-05) -28.87%
1 year (2021-10-05) -74.16%
2 years (2020-10-05) -75.98%
3 years (2019-10-04) 80.24
5 years (2017-10-05) 31.39

Reata Pharmaceuticals financials

Revenue TTM $10 million
Gross profit TTM $-144,503,000
Return on assets TTM -22.86%
Return on equity TTM -159.3%
Profit margin 0%
Book value $1.88
Market capitalisation $936.1 million

TTM: trailing 12 months

Reata Pharmaceuticals share dividends

We're not expecting Reata Pharmaceuticals to pay a dividend over the next 12 months.

Reata Pharmaceuticals share price volatility

Over the last 12 months, Reata Pharmaceuticals's shares have ranged in value from as little as $18.47 up to $114.8. A popular way to gauge a stock's volatility is its "beta".

RETA.US volatility(beta: 1.16)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Reata Pharmaceuticals's is 1.155. This would suggest that Reata Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Reata Pharmaceuticals overview

Reata Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co. , Ltd.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Ask an Expert

You must be logged in to post a comment.

Go to site